AccuGenomics, based in Wilmington, North Carolina, was founded in 2011 by James C. Willey, M.D. The company's innovative spike-in control technology, called SNAQ-SEQ, uses synthetic DNA or RNA internal standards mixed with each sample to provide a more reliable run control approach for next-generation sequencing (NGS) assays. This technology enhances the accuracy of sequencing tests for low abundance biomarkers like circulating tumor DNA (ctDNA) and low titer infectious pathogens such as SARS-CoV-2. By eliminating false positives and reducing false negatives, AccuGenomics' spike-in controls significantly improve the overall accuracy of clinical sequencing tests. The company currently offers PCR-based genetic tests for lung cancer and BCR/ABL mutations, with more tests in development.